Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

Children suffering from Spinal Muscular Atrophy (SMA) – a rare but debilitating genetic condition – are being denied a simple ...

The Syrian girl suffers from spinal muscular atrophy, a rare and serious genetic disorder that affects muscle strength and ...

The baby from Ranaghat in Nadia is suffering from spinal muscular atrophy (SMA) Type I, a condition that causes progressive weakening of the muscles and nerves ...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once ...

Roughly 53 million people in the U.S. provide care to a family member such as a child with complex medical needs, an aging ...

A girl was diagnosed with a rare muscle -wasting condition after she stopped crawling as a baby. Ellie Soares, 11, seemed ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, interim results show.

Spinal Muscular Atrophy known as SMA is a rare genetic disease that affects 1 in 6,000 children. And, tonight, the parents of 6 month old baby Emiliano Flores are calling out for help for their son.